2. >>Therapy Areas

AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV

 
• By Jessica Merrill

FDA approval of the glecaprevir/pibrentasvir combination could help AbbVie fill a gap resulting from declining sales of Viekira Pak, while challenging Gilead's monopoly in some segments of the market.

AbbVie Inc.'s next-generation combination therapy for hepatitis C, Mavyret (glecaprevir/pibrentasvir), will be the first eight-week regimen to treat all non-cirrhotic genotypes of the virus, narrowing the treatment window from what previously was 12 weeks. Marvyret could help AbbVie fill a gap left by declining sales of its first HCV combination Viekira Pak and challenge rival Gilead Sciences Inc.'s near-monopoly, particularly in genotypes 2 and 3 of the virus.

FDA announced the approval of Mavyret Aug. 3 to treat HCV virus genotypes 1-6 without cirrhosis or with mild cirrhosis...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.